Paradigm Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Paradigm Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-4,500	Closed	-$30.6K	–	550
2017 Q2	$30.6K	Sell	4,500 -4,600	-51%	-$34K	0.01%	548
2017 Q1	$85.9K	Buy	+9,100	New	+$90.8K	0.02%	543
2016 Q3	–	Sell	-3,000	Closed	-$12.7K	–	816
2016 Q2	$12.7K	Hold	3,000	–	–	﹤0.01%	758
2016 Q1	$13.1K	Sell	3,000 -6,000	-67%	-$26.7K	﹤0.01%	778
2015 Q4	$55.2K	Buy	+9,000	New	+$59K	0.01%	648
2013 Q4	–	Sell	-53,500	Closed	-$269K	–	859
2013 Q3	$269K	Buy	+53,500	New	+$290K	0.04%	445

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Paradigm Asset Management's PGNX Position: Q3 2017 in Review

Paradigm Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2017, closing a stake of 4,500 shares — an estimated $30.6K sold.

Paradigm Asset Management first reported a position in PGNX in Q3 2013 and held it in 6 quarters. The position peaked at $269K in Q3 2013. 142 funds tracked by Wall St. Rank hold PGNX as of Q3 2017.

Paradigm Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
Paradigm Asset Management sold 4,500 Progenics Pharmaceuticals Inc shares in Q3 2017, an estimated $30.6K.
Paradigm Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q3 2013 and held it in 6 quarters.
Paradigm Asset Management's Progenics Pharmaceuticals Inc position peaked at $269K in Q3 2013.
142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.